Because of Ebola Vaccines capacity to trigger cellular immune responses when antigens are generated and processed intracellularly from cells infected by the recombinant virus, viruses created to act as antigen delivery platforms have grown in popularity. There are two types of viral vectors: replication-competent and replication-deficient. By removing viral genes required for replication and employing cell lines augmented with these viral genes to generate the recombinant viruses, replication-deficient viruses may be created.
These benefits make viral vectors an attractive option, particularly for disorders where cellular immune responses may function as a protective mechanism. Nevertheless, the type of viral vector will determine the type, strength, and longevity of the immune responses that are elicited. The most advanced Ebola Vaccines in clinical development include live vesicular stomatitis virus, recombinant human adenovirus, recombinant simian adenovirus, and viral vectors expressing the full length GP of the Ebola virus (VSV).
Read More- https://cmiblogdailydose.blogspot.com/2023/03/several-ebola-vaccines-are-being-tested.html
